| Name | Title | Contact Details |
|---|
The Law Offices of Mike N. Vo, APLC, is a boutique firm located in the heart of Orange County, California, serving the needs of small business owners. Whether you are an established business owner, start-up business, or free spirited entrepreneur, The Law Offices of Mike N. Vo, APLC, provides business minded individuals with the peace of mind knowing that they have the best and most cost-effective legal representation available, so that they can focus on running their business. With over 16 years of legal experience and having owned a manufacturing company serving mass retail clients such as Sephora and TJMaxx, Mike understands the challenges small business owners face everyday and is committed to finding creative solutions to his clients problems. With The Law Offices of Mike N. Vo, APLC, on your side, we "lead your business through its problems..."
RKL is a provider of internal audit, risk management and investment advisory services for credit unions, manufacturing and distribution industries.
Trisura Guarantee Insurance Company, founded in 2006, is a specialty insurance provider focused on delivering tailored insurance and surety solutions in Canada and the United States. As part of Trisura Group Ltd., the company offers expertise in surety, corporate insurance, warranty, program, and fronting business lines. Trisura aims to simplify insurance for its clients by providing personalized and flexible solutions through a select network of brokers. The company offers a wide range of products, including surety bonds, corporate insurance, casualty insurance, cyber insurance, and specialized warranty and program insurance. Trisura primarily serves corporate clients, including small and medium-sized businesses, addressing their unique insurance needs. With a commitment to exceptional service and community involvement, Trisura allocates a portion of its net underwriting income to charitable causes and engages employees in its giving strategy. The company continues to grow, employing over 150 people and expanding its operations in North America.
DESTINATION DEVELOPMENT Understanding what exists in your destination is important. Knowledge of your cannabis and hemp-related assets directly informs the strategy and program architecture. I engage and educate stakeholders, assess the destination, and develop a bespoke cannabis travel strategy and program that fosters long term success. The strategy may or may not include B2C product development i.e. trail, passport, newsletter. DESTINATION MARKETING The data shows that the cannabis-motivated active leisure travel audience is a high value audience that stays longer and spends more while in a destination. Through a dedicated cannabis travel program, I work with stakeholders to facilitate a steady flow of cannabis and hemp-related content that elevates the cannabis experience story in a sophisticated and brand aligned way. I advise DMOs on B2B and B2C content and marketing strategies. HOTEL SOLUTIONS Hotels are the heart of the travel ecosystem of a destination. Hotels greatly influence the overall experience for visitors. With a focus on guest experience, room nights, and turn-key incremental revenue opportunities, I help hotels understand, prepare for, and serve the cannabis and hemp CBD-interested hotel guest. Solutions include hospitality education, frontline staff support, and revenue generating opportunities in lobby, spa, and in-room.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.